Cue Biopharma, Inc. (CUE) delivered a return of 19.86% over the past year. Since CUE does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Cue Biopharma, Inc. one year ago would be worth $11,986 today, representing a gain of $1,986.

Cue Biopharma, Inc. (CUE) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For CUE, the total return equals the price-only return.

No, Cue Biopharma, Inc. (CUE) underperformed the S&P 500 by 0.98 percentage points over the past year. CUE delivered a total return of 19.86%, compared to the S&P 500's 20.84%. This means a passive S&P 500 index fund outperformed CUE by 0.98pp during this period.

Cue Biopharma, Inc. (CUE) experienced a maximum drawdown of -98.63% over the past year, declining from its peak on 2025-10-09 to its trough on 2026-01-24. The stock recovered to its prior peak by 2026-05-01. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Cue Biopharma, Inc. (CUE)'s long-term returns with dividends reinvested. Over 10 years, the total return is -92.5% (-22.9% CAGR) — $10,000 would have grown to $745. Over 20 years: -92.5% total return (-12.2% CAGR) — $10,000 → $745. Over 30 years: -92.5% total return (-8.3% CAGR) — $10,000 → $745. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Cue Biopharma, Inc.'s best calendar year was 2019 with a total return of 207.7%. Its worst year was 2022 with a total return of -76.8%. This range shows the volatility investors should expect — the difference between the best and worst year is 284.4 percentage points.